Onco-Innovations Engages Investment Bank to Pursue Nasdaq Cross-listing and Potential Concurrent Equity Offering
Rhea-AI Summary
Onco-Innovations (OTCQB:ONNVF) announced on December 7, 2025 that it has engaged a U.S. investment bank to advise on a potential Nasdaq cross-listing and to evaluate a possible concurrent equity financing.
The advisory mandate covers analysis of listing requirements, regulatory and governance considerations, and capitalization strategies to support a U.S. cross-listing. The company said the structure and terms of any financing are not finalized and that there is no assurance a cross-listing or financing will be completed.
Positive
- None.
Negative
- None.
News Market Reaction – ONNVF
On the day this news was published, ONNVF declined 7.56%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
No peers were flagged in the momentum scanner, and no same-day peer headlines were provided, suggesting the move in ONNVF was stock-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Aug 13 | Private placement close | Negative | -7.7% | Closed non-brokered private placement raising funds via units with warrants. |
| Aug 04 | Clinical prep deal | Positive | -7.7% | Avance Clinical agreement to prepare first-in-human trial documentation. |
| Jul 30 | AI oncology project | Positive | -7.7% | Subsidiary Inka Health selected for AI-driven oncology RWE project. |
| Jul 29 | Private placement launch | Negative | -7.7% | Announced non-brokered private placement with units and incentive grants. |
| Jul 11 | AI services agreement | Positive | -7.7% | Redwood AI agreement to support PNKP inhibitor development with AI tools. |
News has repeatedly been followed by negative price reactions, including both financing announcements and R&D/AI collaboration updates.
Over the last several months, Onco-Innovations reported multiple financings and development milestones. In July 2025, it announced and later closed a private placement of $400,000 alongside new options and RSUs, with shares reacting about -7.69% after these financing updates. The company also disclosed AI-driven collaborations and preparation for a first-in-human trial, yet those catalysts similarly saw -7.69% next-day moves. Today’s announcement about a potential Nasdaq cross-listing and concurrent equity financing fits this pattern of strategic funding and development steps.
Market Pulse Summary
The stock moved -7.6% in the session following this news. A negative reaction despite the strategic Nasdaq cross-listing plan would have fit the stock’s history of weak post-news performance, including prior moves of about -7.69% after financings and R&D milestones. The announcement referenced a potential concurrent equity financing, which could raise dilution concerns. Given that shares traded below the $1.45 200-day MA and far under the 52-week high, sentiment around additional capital raising often weighed heavily on the name.
Key Terms
cross-listing financial
AI-generated analysis. Not financial advice.
VANCOUVER, BC / ACCESS Newswire / December 7, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has engaged a U.S. investment bank to serve as its capital markets advisor in connection with the Company's intention to pursue a potential cross-listing of its common shares on the Nasdaq Stock Market LLC ("Nasdaq" or the "Exchange") and to evaluate and structure a potential concurrent equity financing. The structure and terms of the contemplated financing have not yet been finalized.
This engagement forms part of the Company's ongoing evaluation of options intended to support long-term corporate development. The advisory mandate will include analysis and planning related to listing requirements, regulatory considerations and the capitalization strategies necessary to facilitate the potential U.S. cross-listing and concurrent financing.
The Company notes that no assurance can be given that a cross-listing or concurrent financing will be completed, and any such listing would remain subject to meeting applicable regulatory, governance, and exchange requirements.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
Forward-Looking Statements Caution. This news release contains forward-looking statements, including statements regarding the Company's engagement of a U.S. investment bank, the potential U.S. cross-listing of the Company's common shares on the Nasdaq Stock Market, the completion of a potential concurrent equity offering, the anticipated benefits of such a listing and / or equity offering, and the Company's expectations regarding its strategic review process and related capital markets activities. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
FAQ
What did Onco-Innovations (ONNVF) announce on December 7, 2025 about Nasdaq?
Will Onco-Innovations (ONNVF) definitely list on Nasdaq and complete a financing?
What will the investment bank advisory mandate cover for Onco-Innovations (ONNVF)?
Does the December 7, 2025 announcement specify the size or terms of the equity financing for ONNVF?
How should ONNVF shareholders interpret the engagement of a U.S. investment bank?
